title: Teriflunomide.
abstract: Teriflunomide is a novel disease-modifying agent that was recently approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials and is an attractive agent to add to the growing repertoire of available treatments for MS, as it has the benefit of oral administration. Furthermore, existing clinical experience with its parent drug, leflunomide, provides indirect long-term safety data. This review summarizes teriflunomide's pharmacologic properties, pivotal clinical trials, and safety profile, and ends with a discussion of the role of teriflunomide in the context of current and emerging MS treatment options.
authors.affiliation: Department of Neurology (JO), Johns Hopkins University, Baltimore, MD; and Division of Neurology, Department of Medicine (JO, PWO), St. Michael's Hospital, University of Toronto, Toronto, Canada.
authors.forename: Jiwon
authors.initials: J
authors.lastname: Oh
authors.forename: Paul W
authors.initials: PW
authors.lastname: O'Connor
references.citation: J Pharmacol Exp Ther. 1995 Nov;275(2):1043-9
references.pmid: 7473131
references.citation: Intern Med J. 2009 Feb;39(2):95-102
references.pmid: 19220542
references.citation: Mult Scler. 2012 Sep;18(9):1278-89
references.pmid: 22307384
references.citation: Ann Rheum Dis. 2003 Jan;62(1):50-7
references.pmid: 12480669
references.citation: J Biol Chem. 1995 May 26;270(21):12398-403
references.pmid: 7759480
references.citation: N Engl J Med. 2011 Oct 6;365(14):1293-303
references.pmid: 21991951
references.citation: Arch Neurol. 2008 Nov;65(11):1538-9
references.pmid: 19001176
references.citation: Neurology. 2006 Mar 28;66(6):894-900
references.pmid: 16567708
references.citation: Arthritis Rheum. 2005 Sep;52(9):2730-9
references.pmid: 16142756
references.citation: Neurology. 2012 Jun 5;78(23):1877-85
references.pmid: 22622860